Financials

  • Market Capitalization 267.89 M
  • Employee 34
  • Founded 2004
  • CEO Christopher U. Missling Ph.D.
  • Website www.anavex.com
  • Headquarter New York, United States
  • FIGI BBG000C9K8K4
  • Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-7.87
Rapporto prezzo/fatturato
63.29

Related tickers

#NomePrezzo24h %7d %1M %1Y %Valore di MercatoUltimi 7 Giorni
3406
ZNTL
Zentalis Pharmaceuticals, Inc. - common stock
3.77 USD+1.62%-2.58%-19.27%+120.47%270.20 M USD
3411
WHWK
Whitehawk Therapeutics, Inc. - Common Stock
4.71 USD+1.73%-2.48%+18.34%+56.48%268.51 M USD
3420
SRZN
Surrozen, Inc. - Common Stock
22.60 USD+1.80%-4.60%+2.17%+75.19%265.63 M USD
3438
NMRA
Neumora Therapeutics, Inc. - Common Stock
1.38 USD+3.76%-10.97%-15.85%-20.69%259.30 M USD

Notizie